Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Astrazeneca (AZNCF) Return on Equity (2016 - 2025)

Historic Return on Equity for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to 0.26%.

  • Astrazeneca's Return on Equity rose 500.0% to 0.26% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.26%, marking a year-over-year increase of 500.0%. This contributed to the annual value of 0.28% for FY2025, which is 600.0% up from last year.
  • Latest data reveals that Astrazeneca reported Return on Equity of 0.26% as of Q4 2025, which was up 500.0% from 0.25% recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Return on Equity ranged from a high of 0.31% in Q1 2021 and a low of 0.05% during Q2 2022
  • Over the past 5 years, Astrazeneca's median Return on Equity value was 0.19% (recorded in 2023), while the average stood at 0.15%.
  • As far as peak fluctuations go, Astrazeneca's Return on Equity crashed by -3400bps in 2022, and later soared by 2200bps in 2023.
  • Quarter analysis of 5 years shows Astrazeneca's Return on Equity stood at 0.01% in 2021, then skyrocketed by 1135bps to 0.07% in 2022, then soared by 161bps to 0.18% in 2023, then rose by 18bps to 0.21% in 2024, then rose by 23bps to 0.26% in 2025.
  • Its last three reported values are 0.26% in Q4 2025, 0.25% for Q3 2025, and 0.23% during Q2 2025.